BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 12486908)

  • 1. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 8. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
    Bonuccelli U; Colzi A; Del Dotto P
    Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The variability of levodopa response in Parkinson's disease: is sensitization reversible?
    Jabre MG; Bejjani BP
    Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452
    [No Abstract]   [Full Text] [Related]  

  • 15. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
    Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
    Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
    Bode M
    Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pergolide mesylate in Parkinson's disease treatment.
    Pezzoli G; Canesi M; Pesenti A; Mariani CB
    J Neural Transm Suppl; 1995; 45():203-12. PubMed ID: 8748627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.